Price$0.56-0.66 (-54.35%)
2026-04-142026-07-17
News · 26 weeks57-43%
2026-01-252026-07-19
Mix1890d
- SEC Filings7(39%)
- Other6(33%)
- Earnings2(11%)
- Insider1(6%)
- Offering1(6%)
- Analyst1(6%)
Latest news
25 items- ANALYSTMaxim Group initiated coverage on HeartBeam with a new price targetMaxim Group initiated coverage of HeartBeam with a rating of Buy and set a new price target of $2.00
- PRHeartBeam Awarded New U.S. Patent Expanding Acoustic Sensing and Fluid Monitoring Capabilities of Its Cable-Free ECG DevicePatent extends HeartBeam's ECG hardware platform with multi-modal sensing capabilities Acoustic sensors enable HeartBeam’s device to function as a "digital stethoscope" to assess heart valve function Thoracic impedance capability opens the door to heart failure monitoring without a surgical procedure HeartBeam now holds 26 issued patents worldwide, reflecting continued investment in building a durable IP moat around its platform HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the allowance of a new U.S. patent that significantly expands the capabilities of its credit card-si
- SECHeartbeam Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - HeartBeam, Inc. (0001779372) (Filer)
- PRHeartBeam Completes Enrollment in Heart Attack Detection Pilot Study Ahead of ScheduleAccelerated enrollment completion in ALIGN-ASS study underscores HeartBeam’s execution on its key strategic priority of heart attack detectionData analysis is underway, with full results anticipated for presentation at upcoming cardiology conferenceFindings will inform the design of the planned U.S. pivotal study and support the FDA pathwayFuture indication expansion could unlock a large addressable market of millions of patients at riskHeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care through powerful cardiac insights, today announced completion of patient enrollment in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack
- SECSEC Form DEFA14A filed by Heartbeam Inc.DEFA14A - HeartBeam, Inc. (0001779372) (Filer)
- SECHeartbeam Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits8-K - HeartBeam, Inc. (0001779372) (Filer)
- PRHeartBeam Announces Strategic Shift to Accelerate Global Adoption of its Ambulatory ECG Signal Platform and Leadership TransitionCompany will license its 3D ECG signal technology to established partners, moving beyond direct medical device sales Advancing toward heart attack detection as a key expansion of the platform Tailoring its technology to fit each market, while operating with a leaner, more focused structure Company to provide more details on strategy as part of Second Quarter 2026 conference call in August HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced a reorganization to prioritize global market reach and capital efficiency while accelerating execution. The company has aligned its operation
- SECHeartbeam Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - HeartBeam, Inc. (0001779372) (Filer)
- SECSEC Form DEF 14A filed by Heartbeam Inc.DEF 14A - HeartBeam, Inc. (0001779372) (Filer)
- SECSEC Form PRE 14A filed by Heartbeam Inc.PRE 14A - HeartBeam, Inc. (0001779372) (Filer)
- PRHeartBeam Announces New Peer-Reviewed Article Demonstrating Potential to Help Identify Heart Attack Risk at HomePublication in JACC: Advances demonstrates that an algorithm combining the HeartBeam ECG device with patient risk factors and symptoms can accurately identify heart attack risk Study advances the scientific foundation supporting HeartBeam's planned indication expansion into heart attack detection Large market potential with over 20 million patients in the U.S. at risk of a heart attack HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced a peer-reviewed article in JACC: Advances, a journal of the American College of Cardiology, demonstrating that a risk prediction algorithm incorpor
- SECSEC Form 10-Q filed by Heartbeam Inc.10-Q - HeartBeam, Inc. (0001779372) (Filer)
- PRHeartBeam Reports First Quarter 2026 ResultsSigned First Commercial Partners in Leading Concierge Practices ClearCardio™ and Atelier Health Established Flagship Commercial Sites Across New York, Dallas, South Florida and Southern California Strategic Collaboration with Mount Sinai to Accelerate Next-Generation AI-ECG Algorithms, Starting with Heart Attack Detection Strengthened Balance Sheet with $11.5 Million Public Offering Including Full Exercise of Over-Allotment Option Initiated Heart Attack Detection Pilot Study, A Key Step Toward Future FDA Indication Expansion Initiated Pilot Study of First On-Demand 12-Lead ECG Patch to Detect Ischemia Outside the Clinic Management to Host Webcast and Conference Call Today
- PRHeartBeam Initiates Pilot Study of First On-Demand 12-Lead ECG Patch to Detect Ischemia Outside the ClinicAmbulatory patch device designed to aid in detecting ischemia and complex arrythmias Targets a $2 billion market with established reimbursement; ischemia detection has potential to disrupt the patch market which is currently limited to atrial fibrillation detection HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, announced the initiation of a pilot study evaluating its novel on-demand 12-lead ECG patch in patients with suspected coronary artery disease. The study is being conducted at two leading hospitals in Belgrade, Serbia. The initiation of the pilot study represents a significant step in the
- PRHeartBeam Expands Commercial Presence Across Four Key U.S. Markets with Addition of Premier Concierge PracticeLeading concierge practice Atelier Health, led by physicians affiliated with Cedars-Sinai, will now offer HeartBeam to its patients Opens up flagship sites across New York, Dallas, South Florida and Southern California, supporting scalable expansion of HeartBeam technology in preventive cardiology HeartBeam continues to execute on its go-to-market strategy in high-value, direct-pay care environments HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced a commercial agreement with Atelier Health, a premier concierge medical practice led by physicians affiliated with Cedars-Sinai Medic
- PRTELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 RevenuesMALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company's next phase of commercial growth and operational excellence. In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company's 2026 Annual Meeting of Stockholders on June 9, 2026 (the "2026 Annual Meeting"), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial strategy,
- PRHeartBeam to Host First Quarter 2026 Results Conference Call on Wednesday, May 13, 2026 at 4:30 p.m. Eastern TimeHeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, will hold a conference call on Wednesday, May 13, 2026 at 4:30 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2026, and will be providing updates on key strategic growth initiatives, including its limited commercial launch for arrhythmia assessment, and developments on its extended-wear patch, heart attack detection and AI initiatives. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answe
- INSIDERAmendment: Director Ferrari Richard bought $46,000 worth of shares (57,500 units at $0.80), increasing direct ownership by 25% to 286,636 units (SEC Form 4)4/A - HeartBeam, Inc. (0001779372) (Issuer)
- ANALYSTHeartBeam downgraded by D. Boral CapitalD. Boral Capital downgraded HeartBeam from Buy to Hold
- INSIDERSEC Form 4 filed by Cruickshank Tim4 - HeartBeam, Inc. (0001779372) (Issuer)
- INSIDERSEC Form 4 filed by Elfrink Willem4 - HeartBeam, Inc. (0001779372) (Issuer)
- INSIDERSEC Form 4 filed by Jaff Michael R4 - HeartBeam, Inc. (0001779372) (Issuer)
- INSIDERSEC Form 4 filed by Vajdic Branislav4 - HeartBeam, Inc. (0001779372) (Issuer)
- INSIDERSEC Form 4 filed by Ferrari Richard4 - HeartBeam, Inc. (0001779372) (Issuer)
- INSIDERSEC Form 4 filed by Eno Robert Paul4 - HeartBeam, Inc. (0001779372) (Issuer)
BEAT FAQ
7 questionsWhat does Heartbeam Inc. do?
HeartBeam, Inc., a medical technology company, primarily focusing on telemedicine solutions that enable the detection and monitoring of cardiac disease. It focuses on providing diagnostic data to help physicians with care management of patients with cardiovascular disease. The company is developing its telehealth product that comprises a credit card sized electrocardiograms machine and a cloud-based diagnostic software system to address the rapidly growing field of remote patient monitoring. The company was incorporated in 2015 and is based in Santa Clara, California.Where does BEAT stock trade?
Heartbeam Inc. (BEAT) is listed on NASDAQ.What sector and industry is BEAT in?
Heartbeam Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Heartbeam Inc. go public?
Heartbeam Inc. (BEAT) completed its IPO in 2021.What are analysts saying about BEAT?
Heartbeam Inc. has had 8 recent analyst actions on file. The most recent action was from Maxim Group: Buy with a $200.00 price target on 2026-07-14. Recent price targets range from $200.00 to $800.00.What companies are similar to BEAT?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare BEAT side-by-side with any of them on Quantisnow.How can I track BEAT on Quantisnow?
Quantisnow aggregates Heartbeam Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BEAT to receive live email and push alerts on every new disclosure.